Drug Interactions with Antiemetics in Veterinary Patients: Clinical Considerations

By Dr. Zubair Khalid, DVM, MS, PhD · 2026-08-11

Key Takeaways

• Concurrent use of metoclopramide with phenothiazine antiemetics (prochlorperazine, chlorpromazine) significantly increases the risk of extrapyramidal signs due to additive D2 receptor blockade, with cats exhibiting heightened sensitivity.
• 5-HT3 antagonists like ondansetron and dolasetron carry a risk of QT interval prolongation, which is dose-dependent and additive with other QT-prolonging drugs (e.g., fluoroquinolones, macrolides), necessitating baseline ECG in geriatric or cardiac patients.
• Serotonin syndrome can be precipitated by combining metoclopramide (which has 5-HT4 agonism) with other serotonergic drugs (e.g., tramadol, SSRIs), presenting as agitation, hyperthermia, and tremors, and is diagnosed clinically with no confirmatory lab test.
• Metoclopramide's prokinetic effect, mediated by cholinergic transmission, is pharmacodynamically antagonized by anticholinergic drugs (e.g., atropine, glycopyrrolate), potentially diminishing its efficacy in improving gastric emptying.
• Maropitant, an NK-1 receptor antagonist, has uncertain clinical relevance regarding CYP3A4 inhibition in vivo, but caution is advised with potent CYP3A4 inhibitors or inducers due to potential alterations in drug clearance.
• Monitoring for neurologic signs (tremors, rigidity) is critical when combining metoclopramide with serotonergic agents, while ECG monitoring for QT prolongation is paramount for 5-HT3 antagonists used concurrently with other cardiotoxic drugs.

Antiemetic drugs are among the most frequently prescribed medications in small animal practice, yet their interactions with concurrent therapies are often underappreciated. This article examines the clinically relevant drug interactions involving the antiemetic agents most commonly used in dogs and cats: maropitant, metoclopramide, ondansetron, dolasetron, and, where applicable, prochlorperazine and chlorpromazine. The focus is on pharmacodynamic and pharmacokinetic interactions that alter efficacy, increase toxicity, or produce paradoxical effects. The intended reader is the practicing veterinarian who needs a decision-oriented framework for prescribing antiemetics in patients receiving multiple drugs.

The article addresses three core questions. First, which antiemetic combinations are synergistic and which are antagonistic? Second, which concurrent medications create meaningful risk through shared metabolic pathways, additive QT prolongation, or opposing dopaminergic and serotonergic effects? Third, how should the clinician adjust monitoring or drug selection when these interactions are unavoidable? The discussion draws on established receptor pharmacology and regulatory guidance from sources including the MSD Veterinary Manual and the FDA Center for Veterinary Medicine, with the understanding that much of the interaction data in veterinary species is extrapolated from human medicine and requires cautious application.

At a Glance

Emetic Pathways and Receptor Targets

The vomiting reflex integrates input from the chemoreceptor trigger zone (CRTZ), the vestibular system, and vagal afferents from the gastrointestinal tract. The CRTZ lies outside the blood-brain barrier and samples blood and cerebrospinal fluid for emetic toxins. It is rich in dopamine D2, serotonin 5-HT3, neurokinin-1 (NK-1), and histamine H1 receptors. The nucleus tractus solitarius and the central pattern generator for vomiting receive convergent projections from these sites. As reviewed in Mechanisms of Nausea and Vomiting: Current Knowledge and Recent Advances in Intracellular Emetic Signaling Systems, diverse emetic stimuli activate distinct receptor populations but converge on shared intracellular signaling cascades, including NK-1 receptor-mediated neurokinin signaling that appears to be a final common pathway for many stimuli.

This architecture explains why drug interactions at the receptor level can be additive, synergistic, or antagonistic. A drug that blocks D2 receptors in the CRTZ, such as metoclopramide, will not prevent vomiting triggered primarily through 5-HT3 or NK-1 pathways. Conversely, combining a 5-HT3 antagonist with an NK-1 antagonist can produce broader spectrum coverage because they interrupt different afferent arms of the reflex. The clinical implication is that combination antiemetic therapy is rational when the emetic stimulus is multifactorial, but it also multiplies the interaction surface with other drugs the patient is receiving.

Dopaminergic Antagonists: Metoclopramide and Phenothiazines

Metoclopramide is a substituted benzamide that antagonizes D2 receptors in the CRTZ and, at higher doses, acts as a 5-HT4 agonist and 5-HT3 antagonist in the gut. Its prokinetic effect on upper gastrointestinal motility is mediated through 5-HT4 receptor agonism and enhanced acetylcholine release. The phenothiazines used as antiemetics, prochlorperazine and chlorpromazine, also block D2 receptors but with additional H1, alpha-1 adrenergic, and muscarinic antagonism.

The most clinically significant interaction within this class is additive D2 blockade. When metoclopramide is combined with a phenothiazine, the risk of extrapyramidal signs, including akathisia, dystonia, and facial twitching, increases substantially. This is particularly relevant in cats, which appear more sensitive to phenothiazine-induced behavioral changes. The MSD Veterinary Manual cautions that concurrent use of metoclopramide with other dopamine antagonists amplifies these effects. Additionally, both drug classes can lower the seizure threshold, so their combined use in epileptic patients warrants caution.

Metoclopramide also interacts with opioid analgesics at the gut level. Opioids reduce gastrointestinal motility through mu receptor activation, and metoclopramide's prokinetic effect is often insufficient to overcome opioid-induced ileus. The interaction is pharmacodynamic antagonism: the opioid suppresses the cholinergic drive that metoclopramide depends on. In practice, a patient receiving methadone or buprenorphine for abdominal pain may not derive the expected prokinetic benefit from metoclopramide, and the clinician should consider a 5-HT3 antagonist or maropitant for emesis control instead.

Serotonergic Antagonists: Ondansetron and Dolasetron

The 5-HT3 antagonists block serotonin receptors on vagal afferents and in the CRTZ. Ondansetron and dolasetron are the agents most commonly used in veterinary patients, typically reserved for refractory or chemotherapy-induced emesis. Their interaction profile centers on two concerns: QT interval prolongation and serotonin syndrome.

Dolasetron carries a greater risk of QT prolongation than ondansetron, particularly with intravenous administration. The risk is dose-dependent and additive with other QT-prolonging drugs, including fluoroquinolones, macrolides, azole antifungals, and class III antiarrhythmics. The FDA Center for Veterinary Medicine maintains adverse event reporting that has identified cardiac arrhythmias associated with 5-HT3 antagonists in companion animals, though the absolute incidence is low. For patients receiving concurrent QT-prolonging therapy, ondansetron is the safer choice, and baseline electrocardiography should be considered in geriatric patients or those with cardiac disease.

Serotonin syndrome arises from excessive serotonergic tone in the central nervous system. While 5-HT3 antagonists do not increase serotonin release, they can mask the gastrointestinal signs of serotonin excess while allowing neurologic signs to progress. A dog receiving tramadol, a serotonin reuptake inhibitor, and ondansetron may develop agitation, hyperthermia, and tremors without the prodromal vomiting that would otherwise signal serotonergic overload. The interaction is therefore one of masking instead of potentiation, but the clinical consequence is delayed recognition of a potentially fatal syndrome.

Clinical Assessment of Antiemetic Therapy in Polypharmacy Patients

The first step in evaluating a patient receiving antiemetic therapy is a complete medication reconciliation. This includes prescription drugs, over-the-counter products, compounded formulations, and any owner-administered supplements. The timing of administration matters as much as the drug identity. A patient on chronic metoclopramide who develops neurologic signs after starting a new serotonergic drug requires a different response than a patient who received both drugs only once.

The assessment sequence should proceed in a fixed order. Record the antiemetic, its dose, route, and duration. List all concurrent medications with their start dates. Identify the indication for each drug and whether the antiemetic is treating a primary gastrointestinal disorder, a drug-induced emesis, or a systemic disease process. Then evaluate organ function, particularly hepatic and renal status, because both affect drug clearance and metabolite accumulation. Finally, assess the patient's current clinical status, including hydration, perfusion, and neurologic examination.

The decision to continue, adjust, or discontinue an antiemetic hinges on several factors. The severity of the vomiting, the suspected underlying cause, the availability of alternative antiemetic classes, and the risk profile of the concurrent medication all influence the choice. When the antiemetic is treating chemotherapy-induced nausea, the benefit of continuing may outweigh a theoretical interaction risk. When the antiemetic is one of several drugs used for a chronic condition, the risk-benefit calculation shifts.

Serotonin Syndrome Risk in Veterinary Patients

Serotonin syndrome arises from excessive serotonergic activity in the central and peripheral nervous systems. The condition is well documented in human medicine and increasingly recognized in veterinary patients. Ondansetron and other 5-HT3 antagonists block serotonin receptors but do not increase synaptic serotonin concentrations. The greater concern involves drugs that enhance serotonergic transmission, such as metoclopramide, which has agonist activity at 5-HT4 receptors and weak antagonist activity at 5-HT3 receptors.

The clinically relevant interaction occurs when metoclopramide is combined with other serotonergic drugs. These include tramadol, amitriptyline, fluoxetine, and other selective serotonin reuptake inhibitors. The combination can precipitate serotonin syndrome, characterized by agitation, tremors, hyperthermia, hyperreflexia, and in severe cases, seizures. The onset can be acute, within hours of the first combined dose, or gradual over several days.

Recognition depends on a high index of suspicion. Any patient receiving metoclopramide who develops new neurologic signs should be evaluated for serotonin syndrome, particularly if a serotonergic drug was recently added. The diagnosis is clinical. No confirmatory laboratory test exists. The treatment is withdrawal of the offending agents and supportive care, including intravenous fluids, thermoregulation, and sedation when needed.

The evidence base for serotonin syndrome in veterinary patients is limited to case reports and extrapolation from human medicine. The MSD Veterinary Manual provides species-specific guidance on drug dosing and adverse effects, but practitioners should recognize that the threshold for serotonin syndrome in dogs and cats is not precisely defined. When in doubt, avoid the combination or monitor closely for the first 48 to 72 hours after initiation.

Anticholinergic and Prokinetic Combinations

Metoclopramide's prokinetic effect depends on cholinergic transmission. Anticholinergic drugs, including atropine, glycopyrrolate, and some antihistamines, can reduce or abolish this effect. The interaction is pharmacodynamic and predictable. A patient receiving both metoclopramide and an anticholinergic may show diminished gastric emptying and reduced lower esophageal sphincter tone, which can worsen the clinical signs the antiemetic was intended to treat.

This interaction is most relevant in the perioperative setting. Anticholinergics are often used as premedications or during anesthesia. If metoclopramide is part of the antiemetic plan, the timing of administration should be considered. Giving metoclopramide after the anticholinergic effect has waned may preserve its prokinetic activity. Alternatively, a different antiemetic class, such as a 5-HT3 antagonist or maropitant, may be more appropriate when anticholinergic therapy is unavoidable.

The clinical significance of this interaction varies with the dose and duration of anticholinergic therapy. A single perioperative dose of glycopyrrolate may have minimal impact on a patient receiving chronic metoclopramide. Repeated anticholinergic dosing, as might occur in a patient with bradyarrhythmias or excessive salivation, is more likely to produce a meaningful interaction.

Maropitant and Drug Metabolism Considerations

Maropitant is a neurokinin-1 receptor antagonist that blocks substance P signaling in the vomiting center and chemoreceptor trigger zone. It is widely used in dogs and cats for both acute and motion sickness. Maropitant is metabolized by hepatic cytochrome P450 enzymes, primarily CYP2D15 in dogs and CYP1A1 in cats. Drugs that inhibit or induce these enzymes can alter maropitant clearance.

The clinical relevance of these metabolic interactions is uncertain. Maropitant has a wide therapeutic index, and the published evidence for clinically significant interactions with other hepatically metabolized drugs is limited. However, caution is warranted when maropitant is combined with drugs that are potent enzyme inhibitors, such as ketoconazole, or enzyme inducers, such as phenobarbital. The FDA Center for Veterinary Medicine maintains current labeling information that may include specific interaction warnings.

Maropitant also has mild anticholinergic properties at higher doses. This effect is generally not clinically significant at approved doses, but it may become relevant in patients receiving other anticholinergic drugs. The combination of maropitant with a potent anticholinergic could produce additive effects, including dry mouth, tachycardia, and urinary retention.

Monitoring Parameters and Documentation

Monitoring for antiemetic drug interactions requires a structured approach. The parameters to follow depend on the drugs involved and the patient's underlying condition. For patients receiving metoclopramide, serial neurologic examinations are the most important monitoring tool. Any change in mentation, posture, or gait warrants immediate evaluation. For patients receiving ondansetron, the primary concern is QT interval prolongation, although this is more relevant with dolasetron. An electrocardiogram should be considered in patients with cardiac disease, electrolyte abnormalities, or concurrent use of other QT-prolonging drugs.

Documentation should include the drug list, the rationale for each medication, the monitoring plan, and the results of each assessment. When an interaction is suspected, the record should describe the clinical signs, the temporal relationship to drug administration, and the action taken. This documentation supports both patient care and professional accountability.

Checklist for Reviewing Antiemetic Therapy in Polypharmacy Patients

The following checklist provides a structured framework for evaluating any patient receiving antiemetic therapy with concurrent medications.

1. Compile a complete drug list, including all prescription, over-the-counter, and compounded products.
2. Identify the antiemetic class and its mechanism of action.
3. Identify all concurrent drugs that act on serotonergic, dopaminergic, or cholinergic pathways.
4. Assess hepatic and renal function, as these affect drug clearance.
5. Review the AVMA practice resources for current professional guidance on polypharmacy management.
6. Determine whether the antiemetic is treating a primary gastrointestinal disorder or a drug-induced emesis.
7. Evaluate the risk of serotonin syndrome when metoclopramide is combined with serotonergic drugs.
8. Consider the impact of anticholinergic drugs on metoclopramide's prokinetic effect.
9. Assess the potential for metabolic interactions with maropitant.
10. Establish a monitoring plan with specific parameters and action thresholds.
11. Document the assessment, the monitoring results, and any changes to therapy.
12. Re-evaluate the antiemetic at each patient visit and discontinue when no longer indicated.

Species differences affect several of these steps. Cats are more sensitive to the extrapyramidal effects of metoclopramide than dogs. The feline metabolism of maropitant differs from the canine pathway. Cats also have a narrower margin for anticholinergic adverse effects. Production animals are not typically treated with these antiemetics, but when they are, withdrawal periods and regulatory requirements must be verified through WOAH terrestrial animal health standards and local regulatory bodies.

Patient status changes the correct approach. A hospitalized patient can be monitored closely and may tolerate a trial of combination therapy. An outpatient owner may not recognize early signs of serotonin syndrome, making the same combination more hazardous. A patient with hepatic disease may accumulate metoclopramide or maropitant, increasing the risk of adverse effects. A patient with cardiac disease may be more vulnerable to QT prolongation from 5-HT3 antagonists.

Available equipment also matters. Practices with in-house electrocardiography can monitor QT intervals. Practices without this capability should avoid combinations of QT-prolonging drugs or refer the patient for monitoring. Similarly, practices with 24-hour nursing care can observe patients for early neurologic signs, while practices without overnight staffing should exercise greater caution with serotonergic combinations.

Recognized Complications and Early Detection

The most consequential antiemetic interactions in small animal practice present with predictable clinical signatures. Serotonin syndrome, the most dangerous interaction involving ondansetron, dolasetron, or metoclopramide combined with other serotonergic drugs, typically evolves over hours. Early signs include agitation, tremors, hyperthermia, and tachycardia. The discriminating feature separating serotonin syndrome from pain or anxiety is the combination of neuromuscular signs, autonomic instability, and altered mentation appearing after a drug administration event. Serial assessment of rectal temperature, heart rate, pupil size, and proprioceptive responses every two to four hours during suspected serotonin toxicity provides objective trend data. Mechanisms of nausea and vomiting and their intracellular signaling pathways describe the receptor systems through which these drugs converge, and recognizing that convergence clinically is the first step toward intervention.

Metoclopramide-induced extrapyramidal signs, including facial twitching, cervical rigidity, and restlessness, can be mistaken for pain or seizure activity. The temporal relationship to drug administration, usually within one to two hours of a dose, distinguishes these signs from other causes. Stopping the drug and observing for resolution over 12 to 24 hours confirms the diagnosis without requiring additional pharmacologic intervention in most cases.

Maropitant-related hypotension, when it occurs, is most often detected during anesthesia monitoring. A falling mean arterial pressure within 15 to 30 minutes of intravenous maropitant administration, particularly in a patient receiving concurrent acepromazine or an inhalant anesthetic, warrants dose rate review and fluid support. The interaction is dose dependent, and the labelled injection rate should be confirmed against the current FDA animal drug information before administration.

Common Errors and Corrective Actions

Less experienced clinicians frequently prescribe ondansetron to a patient already receiving maropitant without recognizing that the two drugs address different receptor populations. This is not inherently wrong, but it creates a false sense of coverage when the underlying cause, such as a metabolic disturbance or intestinal obstruction, remains unaddressed. The corrective action is to identify the emetic trigger before layering antiemetic drugs.

A second recurring error involves continuing metoclopramide in a patient with suspected gastrointestinal obstruction. The prokinetic effect can mask clinical signs and increase the risk of gastric perforation. Any patient with recurrent vomiting, abdominal pain, or a palpable abdominal mass should have obstruction excluded before prokinetic therapy begins.

A third error is the routine combination of metoclopramide with an anticholinergic such as atropine or glycopyrrolate. The opposing pharmacologic actions produce erratic gastrointestinal motility and unpredictable clinical response. When both drugs are needed for different indications, such as preanaesthetic medication and postoperative nausea, the clinician should separate their administration times and document the rationale.

Students and new graduates also tend to underdose ondansetron when concerned about serotonin syndrome. The result is subtherapeutic effect and continued vomiting, which then prompts additional drug administration. The safer corrective path is to verify the current formulary dose, confirm the absence of interacting serotonergic drugs, and use the labelled dose instead of a fraction of it.

Limitations of Current Evidence

The veterinary literature on antiemetic drug interactions consists largely of extrapolation from human pharmacology, case reports, and small pharmacokinetic studies. Controlled interaction studies in dogs and cats are sparse. The MSD Veterinary Manual provides species-specific dosing and safety information, but it does not resolve questions about chronic combination therapy because those studies have not been performed.

Expert opinion differs on several points. Whether maropitant meaningfully inhibits CYP enzymes at clinically used doses in dogs remains debated. Some clinicians routinely reduce concurrent drug doses when maropitant is added, while others consider the interaction clinically insignificant. The evidence does not currently support either position as definitive. Similarly, the threshold at which metoclopramide combined with ondansetron creates meaningful serotonin syndrome risk in cats is unknown. The prudent approach is to avoid the combination when alternatives exist and to monitor closely when it is necessary.

Referral, Consultation, and Reporting

Referral to a specialist is warranted when vomiting persists despite appropriate antiemetic therapy, when suspected serotonin syndrome does not improve within 12 to 24 hours of discontinuing the offending drugs, or when extrapyramidal signs recur after drug withdrawal. A veterinary internal medicine specialist can pursue advanced diagnostics for occult causes and can manage complex polypharmacy patients with serial therapeutic drug monitoring where available.

Laboratory involvement is indicated when hepatic or renal dysfunction is suspected as a contributor to altered drug clearance. Baseline liver enzyme activity, bile acid testing, and creatinine concentration help predict which patients will accumulate antiemetic drugs or their active metabolites. Serial monitoring of these parameters guides dose adjustments during prolonged therapy.

Regulatory reporting applies when an adverse drug event occurs in a patient receiving an FDA-approved animal drug. The FDA Center for Veterinary Medicine accepts adverse event reports from veterinarians, and reporting suspected interactions contributes to signal detection that label revisions depend upon. AVMA practice resources describe the reporting pathways and the professional obligations surrounding them. When an interaction produces a serious outcome, such as hospitalization or death, the report should be filed promptly with the drug manufacturer and the FDA.

Frequently Asked Questions

How should I manage antiemetic therapy when a client cannot afford serotonergic antagonists?

When cost limits the use of ondansetron or dolasetron, revisit the emetic pathway most relevant to the clinical presentation. Maropitant remains a reasonable first-line option for many canine patients because it targets substance P at the NK-1 receptor, a final common pathway for central and peripheral emetic stimuli. For dopaminergic triggers such as uremia or apomorphine administration, metoclopramide or a phenothiazine may be more appropriate and less expensive. Document the financial constraint in the medical record and state the rationale for the chosen agent. If the patient fails to respond within 24 hours, reassess instead of repeating the same drug. The MSD Veterinary Manual provides species-specific guidance on antiemetic selection and dosing that can inform this decision.

What should I do when an intravenous antiemetic is indicated but venous access is limited?

Subcutaneous administration of maropitant is an accepted alternative in dogs when intravenous access is unavailable, though onset of action is slower. Metoclopramide can be given by continuous subcutaneous infusion in some settings, but this requires careful monitoring of the infusion site and rate. Oral ondansetron or orally disintegrating tablets may be used in cats that tolerate handling, but absorption can be unreliable in patients with active vomiting. In a hospital setting, consider placing a temporary intravenous catheter even if brief, or use intraosseous access in critical patients. Always confirm the route is labeled or supported by current formularies before administration. The FDA Center for Veterinary Medicine publishes label information that specifies approved routes for each product.

How do antiemetic drug interactions differ between dogs and cats?

Cats are more sensitive to the extrapyramidal effects of metoclopramide and phenothiazines, so concurrent use with other dopamine antagonists such as acepromazine requires a lower threshold for dose reduction. Cats also have reduced glucuronidation capacity, which can slow clearance of drugs metabolised through that pathway, although maropitant is primarily metabolised by CYP enzymes in both species. Ondansetron appears better tolerated in cats than in dogs at equivalent weight-based doses, but data are limited. The MSD Veterinary Manual notes species differences in drug metabolism that should guide dosing adjustments. When switching between species, do not assume dose equivalence. Consult a current veterinary formulary for species-specific recommendations.

What records should I keep when an antiemetic interaction is suspected?

Record the suspected interacting drugs, their doses, routes, and administration times, along with the temporal relationship to the adverse event. Note the patient's signalment, concurrent disease, and any laboratory values that support the diagnosis, such as liver enzyme changes with maropitant accumulation. Describe the clinical signs observed and the response to dose adjustment or drug discontinuation. If the reaction is severe or unexpected, report it through the appropriate adverse event reporting pathway. The AVMA practice resources include guidance on adverse event documentation and reporting expectations for veterinary professionals. Clear records also protect against repeated exposure in the same patient and support future prescribing decisions.

How should I explain a drug interaction risk to a client without causing undue alarm?

Frame the discussion around monitoring and safety instead of probability of harm. State that the combination is used commonly and that the veterinary team will watch for specific signs, such as agitation, tremors, or changes in appetite. Give the client two or three concrete observations to report, and explain what to do if those signs appear, such as stopping the medication and calling the clinic. Avoid statistical language that clients may misinterpret. The AVMA antimicrobial stewardship resources model a communication style that is direct, transparent, and focused on shared decision-making, which applies equally to antiemetic prescribing. Written take-home instructions reinforce verbal guidance.

When should I refer a patient with a suspected antiemetic interaction to a specialist?

Refer when the patient develops neurologic signs that do not resolve after discontinuing the suspected drug, when cardiovascular instability is present, or when the patient has pre-existing hepatic or renal disease that complicates drug clearance. Referral is also appropriate when the suspected interaction involves an uncommon drug combination and the local evidence base is thin. Before referral, stabilize the patient, discontinue nonessential medications, and document the timeline of drug administration and clinical signs. The WOAH terrestrial animal health standards emphasize the importance of clear communication across professional boundaries, which applies to referral summaries. Provide the specialist with a complete medication list, including over-the-counter products and supplements.

Related Clinical & Scientific Guides

• Veterinary Formulary Essentials: Navigating Drug References
• Drug Interactions with Antiepileptic Drugs in Veterinary Patients: Managing Polypharmacy
• Drug Interactions with Corticosteroids in Veterinary Patients: A Comprehensive Review

References and Further Reading

• Mechanisms of Nausea and Vomiting: Current Knowledge and Recent Advances in Intracellular Emetic Signaling Systems.. 2021.
• FDA Center for Veterinary Medicine: Animal Drug Information. FDA CVM.
• AVMA Antimicrobial Use and Stewardship. American Veterinary Medical Association.
• MSD Veterinary Manual, Professional Edition. MSD Veterinary Manual.
• American Veterinary Medical Association Practice Resources. American Veterinary Medical Association.
• WOAH Terrestrial Animal Health Code. WOAH.

Related Articles

• Drug Interactions with Opioid Analgesics in Veterinary Patients: Clinical Implications
• Drug Interactions with NSAIDs in Veterinary Patients: Mechanisms and Clinical Management
• Pharmacokinetic Drug Interactions in Veterinary Patients: Mechanisms and Clinical Relevance
• Drug Interactions with Antihypertensive Medications in Veterinary Patients
• Drug Interactions with Antacids and Gastroprotectants in Veterinary Patients

This article is educational professional reference material for veterinary audiences. It is not a substitute for veterinary diagnosis, individual clinical judgment, current product labeling, or applicable regulatory requirements.